Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a X-chromosomally transmitted disorder of the erythrocyte that affects 400 million people worldwide, occurring with increased frequency throughout Africa, Asia, the Mediterranean, and the Middle East. Prevalence of this deficiency has been found to be the gene mutations that affecting encoding of G6PD, which is correlated with the increased risk of neonatal jaundice,neonatal hyperbilirubinemia and drug or food-induced hem-olytic anemia.
Detection of 13 mutations on the 6 exons related to G6PD deficiency
US patented Flow-through Hybridization Technology
Compatible for use with whole blood, cord blood, dried blood spot and amniotic fluid samples
Include amplification control (IC) and hybridization control (Biotin) for monitoring of the entire detection process
Rapid and accurate identification of mutations related to G6PD deficiency in one single test
Easy to operate with 1 hour hands-on time, result available within 3 hours
Simple and direct result interpretation
Effective and cost-efficient
Able to differentiate homozygous/ heterozygous carrier